Register

Login

Vet Times logo
+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • Vet Times jobs home
  • All Jobs
  • Your ideal job
  • Post a job
  • Career Advice
  • Students
About
Contact Us
For Advertisers
NewsClinicalJobs
Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcastsDigital Edition

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

All Jobs

Your ideal job

Post a job

Career Advice

Students

More

All More content

Videos

Podcasts

Digital Edition


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2025

IPSO_regulated

24 Oct 2023

Medium chain triglycerides – their role in brain health

author_img

Cecilia Villaverde

Job Title



Medium chain triglycerides – their role in brain health

Image © freshidea / Adobe Stock

Image © freshidea / Adobe Stock

In healthy animals, glucose is the primary energy source used by the brain, which is required as a continuous supply due to lack of storage capabilities in this organ. The brain uses a large proportion of body glucose; for example, in humans, it consumes 20% (Mergenthaler et al, 2013).

In certain neurological conditions, brain glucose metabolism becomes impaired. This has been identified in epileptogenic brain regions in humans, rodents and dogs (Han et al, 2021), as well as in people affected by Alzheimer’s disease (Pan et al, 2018). Overall, cerebral glucose metabolism is reduced in healthy ageing humans and animals, and is significantly lower in people with Alzheimer’s disease (Pan et al, 2018).

Medium chain triglycerides

Medium chain triglycerides (MCTs) are comprised of a glycerol backbone attached to three medium chain fatty acids (MCFA), which are saturated.

Medium chain length fatty acids contain between 6 and 12 carbon atoms, which differentiates them from either short chain or long chain fatty acids (Jadhav et al, 2022). These MCTs have been found to have effects on brain activity – especially caprylic and capric acid (Berk et al, 2019; Table 1).

​Table 1. Medium chain fatty acids
C6 Hexanoic acid Caproic acid
C8 Octanoic acid Caprylic acid
C10 Decanoic acid Capric acid
C12 Dodecanoic acid Lauric acid

MCTs provide fewer calories compared to long chain triglycerides (LCT; Figure 1). The net energy value of MCTs has been calculated at 6.8 plus-minus 0.15 [CV1] kcal/g, which is less than that of LCTs in typical fats (9 kcal/g; Matulka et al, 2009).

However, the calories provided by MCT supplementation should be accounted for as part of the daily caloric intake in all patients – especially in patients where weight control is an issue.

Calories not coming from the main food can result in nutrient dilution, and the overall recommendation is to keep all unbalanced items below 10% of the daily calories (Freeman et al, 2011).

When MCTs are ingested, the MCFAs are initially released from the glycerol backbone by the enzyme lipase.

Due to their shorter chain length, MCFAs are believed to be mainly transported via the hepatic portal vein to the liver for immediate metabolism rather than via the lymphatic system, as opposed to longer, more hydrophobic fatty acids, but data is still lacking in this area.

Within the liver, they undergo a process of β-oxidation to form ketone bodies, a source of immediate energy (Matulka et al, 2009). The transport of MCFAs into the mitochondrial matrix for β-oxidation does not require the carnitine shuttle system that is necessary for long chain fatty acids and, therefore, MCFAs are metabolised at a quicker rate when compared with LCTs (Law et al, 2018).

Unlike other fatty acids, MCFAs are not primarily transported to the adipose tissue for storage (Jadhav et al, 2022).

Figure 1. MCTs provide fewer calories compared to long chain triglycerides.

Role of MCTs in neurological conditions

MCTs can provide an alternative energy source to glucose in the brain, with both ketone bodies and MCFAs having the ability to cross the blood-brain-barrier (Molina 2020).

The addition of MCTs to the diet has been shown to increase mitochondrial function in dogs, increase metabolic synthesis of polyunsaturated fatty acids and their uptake, and inhibit excitatory neurotransmission in brain tissue (Molina et al, 2020; Chang et al, 2016; Berk et al, 2019). These are the suggested modes of action of the positive effects of MCT supplementation stated at a later point, although knowledge in this area is, as yet, incomplete. The effects may also vary depending on the different specific MCFAs used.

Studies have shown that dietary MCTs can reduce seizure frequency in some dogs with epilepsy (Law et al, 2015; Han et al, 2021) together with medical management. Additionally, behavioural changes, such as increased excitability, chasing behaviours and reduced trainability, have been seen in epileptic dogs, and these can also be improved with MCT supplementation (Packer et al, 2016), suggesting they may have applications in stress and behavioural management.

MCTs also have suggested uses in dogs affected by cognitive dysfunction syndrome (CDS). Research suggests that MCT-enriched diets can improve the clinical signs of CDS in senior dogs, not affected by concurrent epilepsy (Pan et al, 2018).

Compared to the general canine population, dogs with epilepsy develop cognitive impairments at an earlier age (four to six years), due to a quicker onset and reduced life expectancy (Berk et al, 2021; Packer et al, 2018).

MCT supplementation in epileptic dogs was shown to significantly improve spatial working memory, problem solving and owner-reported trainability (Berk et al, 2021). Dietary MCTs could, therefore, be used to support healthy brain function in older dogs, including those patients affected by epilepsy and CDS.

Summary

In summary, research has demonstrated the benefits of MCTs in improving neurological health in dogs, in particular those with epilepsy and those with CDS.

Therefore, MCT supplementation (via an enriched diet or a supplement) is a consideration for the adjunctive management of these conditions in practice.